Key result
Prostaglandin E1 infusions achieved clinical improvement at all doses, with side effects being dose-related and no serious side effects noted at 0.005 to 0.01 micrograms/kg/minute.
Why the study?
Does intravenous prostaglandin E1 safely improve clinical status in neonates with suspected duct-dependent cardiac malformations?
Does intravenous prostaglandin E1 safely improve clinical status in neonates with suspected duct-dependent cardiac malformations?
Answers are grounded in this paper and cite their sources.
Low-dose intravenous prostaglandin E1 (0.005 to 0.01 micrograms/kg/minute) is an effective and safe initial regimen for stabilizing neonates with suspected duct-dependent cardiac defects prior to transfer.
Fifty two sick neonates with major duct dependent cardiac defects were given short term intravenous infusions of prostaglandin E1 (alprostadil) in doses varying between 0.005 and 0.1 micrograms/kg/minute. The object of the study was to try to achieve an effective but safe regiment that could be instituted as soon as such a diagnosis was suspected. Effective clinical improvement was achieved at each dosage but the incidence of side effects seemed to be dose related, and no serious side effects were noted at a dosage of 0.005 to 0.01 micrograms/kg/minute. It is recommended that a low dosage regimen be started before transfer to a paediatric cardiac centre.
No takes yet. Share an insight, caveat, or question.
K A Hallidie-Smith (1984) studied major duct dependent cardiac defects (n=52). Prostaglandin E1 (alprostadil) was evaluated on Clinical improvement and side effects. Prostaglandin E1 infusions achieved clinical improvement at all doses, with side effects being dose-related and no serious side effects noted at 0.005 to 0.01 micrograms/kg/minute.
Synapse has enriched 10 related papers. Consider them for comparative context: